Bridgewater Associates LP trimmed its stake in agilon health, inc. (NYSE:AGL - Free Report) by 79.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,539 shares of the company's stock after selling 92,761 shares during the period. Bridgewater Associates LP's holdings in agilon health were worth $47,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently modified their holdings of the company. Oak Thistle LLC purchased a new stake in shares of agilon health in the 4th quarter worth approximately $25,000. Ieq Capital LLC acquired a new position in agilon health during the 4th quarter valued at about $26,000. Signaturefd LLC raised its position in shares of agilon health by 143.0% in the 4th quarter. Signaturefd LLC now owns 14,388 shares of the company's stock valued at $27,000 after purchasing an additional 8,467 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of agilon health in the fourth quarter worth $33,000. Finally, Cerity Partners LLC purchased a new position in agilon health in the 4th quarter worth $34,000.
agilon health Trading Up 1.8 %
Shares of AGL stock traded up $0.07 on Friday, hitting $3.89. The stock had a trading volume of 3,612,723 shares, compared to its average volume of 4,830,383. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.29 and a quick ratio of 1.29. The firm has a market capitalization of $1.61 billion, a P/E ratio of -4.14 and a beta of 0.38. The company's 50 day moving average price is $4.19 and its 200-day moving average price is $3.14. agilon health, inc. has a 1 year low of $1.50 and a 1 year high of $7.73.
Wall Street Analysts Forecast Growth
AGL has been the topic of several recent research reports. Cowen reaffirmed a "hold" rating on shares of agilon health in a report on Tuesday, April 15th. Robert W. Baird reduced their target price on agilon health from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Tuesday, April 15th. Needham & Company LLC reiterated a "hold" rating on shares of agilon health in a report on Friday, March 21st. Sanford C. Bernstein raised shares of agilon health from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $3.30 to $8.50 in a research note on Tuesday, April 8th. Finally, TD Cowen upped their price target on agilon health from $3.50 to $6.00 and gave the company a "hold" rating in a research report on Tuesday, April 15th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, agilon health has an average rating of "Hold" and a consensus price target of $4.81.
View Our Latest Report on AGL
About agilon health
(
Free Report)
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.
See Also

Before you consider agilon health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and agilon health wasn't on the list.
While agilon health currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.